172 related articles for article (PubMed ID: 35762021)
1. Ambulatory fludrocortisone suppression test in the diagnosis of primary aldosteronism: Safety, accuracy and cost-effectiveness.
Carasel A; Calissendorff J; Avander K; Shabo I; Volpe C; Falhammar H
Clin Endocrinol (Oxf); 2022 Dec; 97(6):730-739. PubMed ID: 35762021
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the saline infusion test and the fludrocortisone suppression test for the diagnosis of primary aldosteronism.
Willenberg HS; Vonend O; Schott M; Gao X; Blondin D; Saleh A; Rump LC; Scherbaum WA
Horm Metab Res; 2012 Jun; 44(7):527-32. PubMed ID: 22689209
[TBL] [Abstract][Full Text] [Related]
3. Re-evaluation of the fludrocortisone test: duration, NaCl supplementation and cut-off limits for aldosterone.
Westerdahl C; Bergenfelz A; Larsson J; Nerbrand C; Valdemarsson S; Wihl A; Isaksson A
Scand J Clin Lab Invest; 2009; 69(2):234-41. PubMed ID: 18951242
[TBL] [Abstract][Full Text] [Related]
4. Comparison of confirmatory tests for the diagnosis of primary aldosteronism.
Mulatero P; Milan A; Fallo F; Regolisti G; Pizzolo F; Fardella C; Mosso L; Marafetti L; Veglio F; Maccario M
J Clin Endocrinol Metab; 2006 Jul; 91(7):2618-23. PubMed ID: 16670162
[TBL] [Abstract][Full Text] [Related]
5. Seated saline suppression testing for the diagnosis of primary aldosteronism: a preliminary study.
Ahmed AH; Cowley D; Wolley M; Gordon RD; Xu S; Taylor PJ; Stowasser M
J Clin Endocrinol Metab; 2014 Aug; 99(8):2745-53. PubMed ID: 24762111
[TBL] [Abstract][Full Text] [Related]
6. Aldosterone LC-MS/MS Assay-Specific Threshold Values in Screening and Confirmatory Testing for Primary Aldosteronism.
Guo Z; Poglitsch M; McWhinney BC; Ungerer JPJ; Ahmed AH; Gordon RD; Wolley M; Stowasser M
J Clin Endocrinol Metab; 2018 Nov; 103(11):3965-3973. PubMed ID: 30137438
[TBL] [Abstract][Full Text] [Related]
7. High rate of detection of primary aldosteronism, including surgically treatable forms, after 'non-selective' screening of hypertensive patients.
Stowasser M; Gordon RD; Gunasekera TG; Cowley DC; Ward G; Archibald C; Smithers BM
J Hypertens; 2003 Nov; 21(11):2149-57. PubMed ID: 14597859
[TBL] [Abstract][Full Text] [Related]
8. Primary aldosteronism among newly diagnosed and untreated hypertensive patients in a Swedish primary care area.
Westerdahl C; Bergenfelz A; Isaksson A; Nerbrand C; Valdemarsson S
Scand J Prim Health Care; 2011 Mar; 29(1):57-62. PubMed ID: 21323498
[TBL] [Abstract][Full Text] [Related]
9. Measurement of Equilibrium Angiotensin II in the Diagnosis of Primary Aldosteronism.
Guo Z; Poglitsch M; McWhinney BC; Ungerer JPJ; Ahmed AH; Gordon RD; Wolley M; Stowasser M
Clin Chem; 2020 Mar; 66(3):483-492. PubMed ID: 32068832
[TBL] [Abstract][Full Text] [Related]
10. Outpatient screening tests for primary aldosteronism.
Dunn PJ; Espiner EA
Aust N Z J Med; 1976 Apr; 6(2):131-5. PubMed ID: 1067811
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Seated With Recumbent Saline Suppression Testing for the Diagnosis of Primary Aldosteronism.
Stowasser M; Ahmed AH; Cowley D; Wolley M; Guo Z; McWhinney BC; Ungerer JP; Gordon RD
J Clin Endocrinol Metab; 2018 Nov; 103(11):4113-4124. PubMed ID: 30239841
[TBL] [Abstract][Full Text] [Related]
12. Seated Saline Suppression Test Is Comparable With Captopril Challenge Test for the Diagnosis of Primary Aldosteronism: A Prospective Study.
Liu B; Hu J; Song Y; He W; Cheng Q; Wang Z; Feng Z; Du Z; Xu Z; Yang J; Li Q; Yang S;
Endocr Pract; 2021 Apr; 27(4):326-333. PubMed ID: 33779561
[TBL] [Abstract][Full Text] [Related]
13. [Diagnosis and treatment outcome in primary aldosteronism based on a retrospective analysis of 187 cases].
Szücs N; Gláz E; Varga I; Tóth M; Kiss R; Patócs A; Jakab C; Perner F; Járay J; Horányi J; Dabasi G; Molnár F; Major L; Füto L; Rácz K; Tulassay Z
Orv Hetil; 2006 Jan; 147(2):51-9. PubMed ID: 16509213
[TBL] [Abstract][Full Text] [Related]
14. [Re-evaluation of the diagnostic value and optimal cutoff point of captopril challenge test in diagnosis of primary aldosteronism].
Luo Y; He WW; Cheng QF; Yang SM; Du ZP; Mei M; Xu ZX; Hu JB; Wang KR; He YF; Li QF; Song Y
Zhonghua Nei Ke Za Zhi; 2022 Jan; 61(1):60-65. PubMed ID: 34979771
[No Abstract] [Full Text] [Related]
15. [High prevalence of undiagnosed primary hyperaldosteronism among patients with essential hypertension].
Mosso L; Fardella C; Montero J; Rojas P; Sánchez O; Rojas V; Rojas A; Huete A; Soto J; Foradori A
Rev Med Chil; 1999 Jul; 127(7):800-6. PubMed ID: 10668287
[TBL] [Abstract][Full Text] [Related]
16. Should aldosterone suppression tests be conducted during a particular phase of the menstrual cycle, and, if so, which phase? Results of a preliminary study.
Ahmed AH; Gordon RD; Ward G; Wolley M; Kogovsek C; Stowasser M
Clin Endocrinol (Oxf); 2015 Sep; 83(3):303-7. PubMed ID: 25523596
[TBL] [Abstract][Full Text] [Related]
17. Screening and diagnosis of primary aldosteronism.
Rayner BL
Cardiovasc J S Afr; 2002; 13(4):166-70. PubMed ID: 12389057
[TBL] [Abstract][Full Text] [Related]
18. Primary aldosteronism: inability to differentiate unilateral from bilateral adrenal lesions by various routine clinical and laboratory data and by peripheral plasma aldosterone.
Vetter H; Siebenschein R; Studer A; Witassek F; Furrer J; Glänzer K; Siegenthaler W; Vetter W
Acta Endocrinol (Copenh); 1978 Dec; 89(4):710-25. PubMed ID: 213920
[TBL] [Abstract][Full Text] [Related]
19. Fludrocortisone suppression test in normal subjects, in patients with essential hypertension and in patients with various forms of aldosteronism.
Lund JO; Nielsen MD
Acta Endocrinol (Copenh); 1980 Jan; 93(1):100-7. PubMed ID: 6986736
[TBL] [Abstract][Full Text] [Related]
20. High frequency of primary hyperaldosteronism among hypertensive patients from a primary care area in Sweden.
Westerdahl C; Bergenfelz A; Isaksson A; Wihl A; Nerbrand C; Valdemarsson S
Scand J Prim Health Care; 2006 Sep; 24(3):154-9. PubMed ID: 16923624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
